Amgen Acquires KAI Pharmaceuticals for $315,000,000
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=60d7936b-049f-4caf-840c-f65e003b7385&Preview=1 -
Date
4/10/2012 -
Company Name
KAI Pharmaceuticals -
Mailing Address
270 Littlefield Avenue South San Francisco, CA 94080 -
Company Description
KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials. -
Website
http://www.kaipharmaceuticals.com -
Transaction Type
M&A -
Transaction Amount
$315,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
The acquisition will be paid for with all cash.
